Journal Mobile Options
Table of Contents
Vol. 28, No. 3, 2009
Issue release date: October 2009
Dement Geriatr Cogn Disord 2009;28:225–232
(DOI:10.1159/000238394)

Primary Health Care Use and Reasons for Hospital Admissions in Dementia Patients in France: Database Study for 2007

Tuppin P. · Kusnik-Joinville O. · Weill A. · Ricordeau P. · Allemand H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: To identify outpatient and hospital health care usage among dementia patients compared to controls. Methods: Analysis of the French National Health Insurance general regime reimbursement database, linked to the national hospitalization database for 2007; 258,809 subjects over the age of 60 with dementia were compared to a sample of 88,296 controls. Results: Dementia patients more frequently had at least one annual visit to private psychiatrists and neurologists (21.9%, relative risk, RR = 7.0), nursing care (52%, RR = 1.3), physiotherapy (37%, RR = 1.45), and hospitalization (40.8%, RR = 1.7), and they less frequently consulted other private specialists (62%, RR = 0.85). Many diagnosis groups were significantly more frequent in dementia patients: nervous system (RR = 5.3), psychiatry (RR = 9.1), respiratory medicine (RR = 1.8), unspecified (RR = 2.4). Hospitalizations for endoscopy, radiotherapy, chemotherapy, and treatment of disabilities such as cataracts (RR = 0.7) were less frequent. Higher relative levels of health care use decreased with age for dementia patients. Conclusions: Although the use of some forms of health care can be explained by the clinical condition induced by dementia, others must be interpreted in light of modes of medical and social management and ethical justification for screening and investigations.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al: Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(S5):S4–S9.
  2. Alzheimer’s Association: Alzheimer’s disease facts and figures. Alzheimers Dement 2008;4:110–133.
  3. Burns A, Iliffe S: Alzheimer’s disease. BMJ 2009;338:b158.
  4. Burns A, Iliffe S: Dementia. BMJ 2009;338:b75.
  5. Kuo TC, Zhao Y, Weir S, Kramer MS, Ash AS: Implications of comorbidity on costs for patients with Alzheimer disease. Med Care 2008;46:839–846.
  6. Zhao Y, Kuo TC, Weir S, Kramer MS, Ash AS: Healthcare costs and utilization for Medicare beneficiaries with Alzheimer’s. BMC Health Serv Res 2008;8:108.
  7. Jönsson L, Eriksdotter Jönhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G, Nygaard H, Andreasen N, Winblad B, Wimo A: Determinants of costs of care for patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2006;21:449–459.
  8. Fillit H, Hill JW, Futterman R: Health care utilization and costs of Alzheimer’s disease: the role of co-morbid conditions, disease stage and pharmacotherapy. Fam Med 2002;34:528–535.
  9. Sloan FA, Taylor DH Jr: Effect of Alzheimer disease on the cost of treating other diseases. Alzheimer Dis Assoc Disord 2002;16:137–143.
  10. Ramaroson H, Helmer C, Barberger-Gateau P, Letenneur L, Dartigues JF: Prévalence de la démence et de la maladie d’Alzheimer chez les personnes de 75 ans et plus: données réactualisées de la cohorte Paquid. Rev Neurol 2003;159:405–411.
  11. Mashta O: Number of people in UK with dementia will more than double by 2050. BMJ 2007;334:447.
  12. Natalwala A, Potluri R, Uppal H, Heun R: Reasons for hospital admissions in dementia patients in Birmingham, UK, during 2002–2007. Dement Geriatr Cogn Disord 2008;26:499–505.
  13. Balardy L, Voisin T, Cantet C, Vellas B; REAL.FR Group: Predictive factors of emergency hospitalisation in Alzheimer’s patients: results of one-year follow-up in the REAL.FR cohort. J Nutr Health Aging 2005;9:112–116.
  14. Andrieu S, Reynish E, Nourhashemi F, Shakespeare A, Moulias S, Ousset PJ, Sagnier P, Richard A, Albarede JL, Vellas B: Predictive factors of acute hospitalization in 134 patients with Alzheimer’s disease: a one year prospective study. Int J Geriatr Psychiatry 2002;17:422–426.
  15. Nourhashémi F, Andrieu S, Sastres N, Ducassé JL, Lauque D, Sinclair AJ, Albarède JL, Vellas BJ: Descriptive analysis of emergency hospital admissions of patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:21–25.
  16. Löppönen M, Räihä I, Isoaho R, Vahlberg T, Kivelä SL: Diagnosing cognitive impairment and dementia in primary health care – a more active approach is needed. Age Ageing 2003;32:606–612.
  17. Pariente A, Helmer C, Merliere Y, Moore N, Fourrier-Réglat A, Dartigues JF: Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008;17:655–660.
  18. Haute Autorité de Santé (HAS): Recommandations professionnelles: diagnostic et prise en charge de la maladie d’Alzheimer et des maladies apparentées. Paris, HAS, 2008. (www.has-sante.fr).
  19. Cameron ID, Kurrle S: Preventing falls in elderly people living in hospitals and care homes. BMJ 2007;334:53–54.
  20. Carter MW, Porell FW: Vulnerable population at risk of potentially avoidable hospitalisation: the case of nursing home residents with Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2005;20:349–358.
  21. Sanderson M, Wang J, Davis DR, Lane MJ, Cornman CB, Fadden MK: Co-morbidity associated with dementia. Am J Alzheimers Dis Other Demen 2002;17:73–78.
  22. Rosenwax L, McNamara B, Zilkens R: A population-based retrospective cohort study comparing care for Western Australians with and without Alzheimer’s disease in the last year of life. Health Soc Care Community 2008;17:36–44.
  23. Zekry D, Herrmann FR, Grandjean R, Meynet MP, Michel JP, Gold G, Krause KH: Demented versus non-demented very old inpatients: the same comorbidities but poorer functional and nutritional status. Age Ageing 2008;37:83–89.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50